Compare Standard Lithium Ltd (SLI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs GeneDx Holdings Corp — how do they compare? Standard Lithium Ltd trades at $2.42 (market cap $604.50M), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: GeneDx Holdings Corp is far larger — about 4× Standard Lithium Ltd's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| SLI | WGS | |
|---|---|---|
Market Cap | $604.50M | $2.44B |
Sector | Basic Materials | Technology |
52-Week High | $5.65 | $167.51 |
52-Week Low | $1.93 | $34.51 |
Enterprise Value | $467.42M | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $2.41, down 4.74% on the day, with technical indicators showing a bullish trend despite recent price weakness. The company maintains strong analyst support with 100% buy ratings from 3 analysts, reflecting optimism about its South West Arkansas lithium project development. Recent earnings show improved performance with two consecutive quarterly beats, though the company remains unprofitable with negative ROE and ROA. Institutional interest is growing, with Amundi increasing its stake by 64.9% in Q1 2026 according to SEC filings.
The investment case centers on SLI's transition to production status with major project de-risking events, including a $225M DOE grant and construction contracts. However, significant execution risks remain as the company burns cash with negative operating cash flow. The path to profitability depends on successful project completion and lithium market conditions, creating both substantial upside potential and meaningful downside risk for investors.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
